An Open-Label Study of Azetukalner in Major Depressive Disorder
NCT06922110 · X-NOVA-OLE Phase 3Active, not recruiting
- Lead sponsor
- Xenon Pharmaceuticals Inc. (Industry)
- Enrollment
- 460 (estimated)
- Start date
- 18 Mar 2025
- Primary completion
- Jan 2027 (estimated)
- Study completion
- 1 Mar 2027
- Last update posted
- 13 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- Azetukalner Drug
Conditions and primary outcome
- Major Depressive Disorder
Primary outcome
Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interest (From the start of treatment in the open-label extension study through 8 weeks after the last dose)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06922110.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06922110 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.